Profile banner
Peter Crane

Peter Crane

Biotechnology professional and founder in human resilience

Oxford, UK
Joined August 2025

Network

7.9K connections
๐Ÿ’ฐ
Deep Tech Investors
๐Ÿ’ก
Biotech Founders Leaders
๐ŸŽ“
Oxford Bio Ecosystem
๐Ÿค–
AI Bio Innovators
๐Ÿš€
Lunar Ventures Team
โš–๏ธ
...
๐Ÿงฌ
Entelo Bio Team

Summary

Peter Crane is a dedicated biotechnology professional and entrepreneur with a strong focus on human resilience. He is the Co-founder and CEO of Entelo Bio, a precision medicine company utilizing gene sequencing and machine learning to decode complex biology for novel therapeutics. His work aims to deliver high-density insights at the cellular level and de-risk clinical trials. peterkcrane+3
He possesses significant experience in venture capital, serving as a Venture Partner at Lunar Ventures and previously at Luminous Ventures and Outsized Ventures. In these roles, he has focused on investments in TechBio, supporting early-stage companies at the intersection of computer science and biology/chemistry. lunar+3
Peter is a chemical biologist by training, holding a DPhil from Oxford University. His career trajectory has evolved from basic wet lab science to computational approaches, and ultimately to company building, driven by a desire to create a tangible impact on patients' lives. peterkcrane+3
He is an advocate for innovation in biopharma, particularly in augmented intelligence and Computer Aided Biology, pushing for digital transformation in the lab to enhance scientific research and accelerate drug discovery. He has written on these topics and believes in empowering scientists with advanced technologies. technologynetworks+1
Peter is actively involved in the UK's biotech ecosystem, often contributing to discussions on industrial strategy and fostering founder-friendly environments. He engages in public discourse regarding policies that impact startup growth and retention in the UK. nitter+1

Work

Education

Projects

Notes

MCMorris Claysaid
PCPeter Crane
is one of the most effective senior leaders they've seen in the biotech or life sciences space.

Oct 24, 2025